Valentina Galiano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Valentina Galiano has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Emanuele Garzia
Reproductive Medicine Unit, Department of Mother and Child, San Paolo Hospital Medical School, ASST Santi Paolo e Carlo, 20142 Milan, Italy
5 shared publications - Anna Maria Marconi
Department of Obstetrics and Gynecology, San Paolo Hospital Medical School, University of Milano, Milano, Italy
3 shared publications - Giovanni Marfia
Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
3 shared publications - Laura Guarnaccia
Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
2 shared publications - Patrizia Sulpizio
Reproductive Medicine Unit, Department of Mother and Child, San Paolo Hospital Medical School, ASST Santi Paolo e Carlo, Milan, Italy
2 shared publications - Stefania Elena Navone
Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
2 shared publications
Latest Publications
- 28 November 2024
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 31 (1) , 45-49
Diagnostic pitfalls in ovarian androgen-secreting tumors in postmenopausal women with rapidly progressed severe hyperandrogenism
Objective: Sex cord-stromal neoplasms of the ovary are rare tumors and a very infrequent cause of androgen excess and virilization in women. We report two cases of postmenopausal women with rapidly progressive signs of virilization and negative or indeterminate imaging for pelvic masses. Methods: Both patients underwent a complete hormone profile, inconclusive transvaginal ultrasound and contrast-enhanced abdominopelvic computed tomography. Results: Serum hormone analysis revealed for both cases a marked increase in serum total testosterone (T). In the first woman, Δ-4 androstenedione (Δ-4 A), dehydroepiandrosterone-sulfate (DHEA-S) and cortisol levels were in a normal range for age. In the second, Δ-4 A and DHEA-S levels were below the reference range. For both women, an ovarian source of androgens was suspected and bilateral laparoscopic oophorectomy was performed. Ovarian histology demostrated bilateral Leydig cell tumor (LCT) in the first case and bilateral ovarian thecoma in the second. After surgery, total testosterone returned to normal levels and clinical symptoms subsided. Conclusions: In cases of postmenopausal androgen excess, physicians must rule out relatively rare androgen-producing tumors originating from the adrenals or ovaries. Regardless of imaging evaluation, our report highlights the importance of prompt and careful clinical and hormonal evaluation to ensure appropriate and timely treatment for the patient.
- 28 November 2024
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 31 (1) , 45-49
Diagnostic pitfalls in ovarian androgen-secreting tumors in postmenopausal women with rapidly progressed severe hyperandrogenism
Objective: Sex cord-stromal neoplasms of the ovary are rare tumors and a very infrequent cause of androgen excess and virilization in women. We report two cases of postmenopausal women with rapidly progressive signs of virilization and negative or indeterminate imaging for pelvic masses. Methods: Both patients underwent a complete hormone profile, inconclusive transvaginal ultrasound and contrast-enhanced abdominopelvic computed tomography. Results: Serum hormone analysis revealed for both cases a marked increase in serum total testosterone (T). In the first woman, Δ-4 androstenedione (Δ-4 A), dehydroepiandrosterone-sulfate (DHEA-S) and cortisol levels were in a normal range for age. In the second, Δ-4 A and DHEA-S levels were below the reference range. For both women, an ovarian source of androgens was suspected and bilateral laparoscopic oophorectomy was performed. Ovarian histology demostrated bilateral Leydig cell tumor (LCT) in the first case and bilateral ovarian thecoma in the second. After surgery, total testosterone returned to normal levels and clinical symptoms subsided. Conclusions: In cases of postmenopausal androgen excess, physicians must rule out relatively rare androgen-producing tumors originating from the adrenals or ovaries. Regardless of imaging evaluation, our report highlights the importance of prompt and careful clinical and hormonal evaluation to ensure appropriate and timely treatment for the patient.
- Open Access
- 27 June 2023
- Vol. 27 (1) , 30-32
Asymptomatic 39 Weeks Abdominal Pregnancy – Video Report of a Case Occurred in Ivory Coast Resulting in a Live Birth
Despite the current advances in antenatal care and imaging methodologies in obstetrics, cases of advanced abdominal pregnancies are still reported, mostly in low- and middle-income countries where frequently only a few perinatal checks are performed and where these methodologies are sometimes not adopted in obstetrical outpatient settings. We report the video of a case of a 20-year-old I gravida Ivorian patient, sent to CHU de T reichville in Abidjan, Ivory Coast, for management of abdominal 39 weeks pregnancy after routine antenatal care. She was asymptomatic with a live foetus in transverse lie position. The anamnesis revealed four prenatal checks without ultrasound evaluation, the first one at 24 weeks of pregnancy. Emergency median longitudinal sub-umbilical laparotomy incision was performed. Foetal extraction was realized by transplacental incision due to omental placental implantation. A live female baby weighting 3350 grams was delivered, presenting bilateral clubfeet and an enlarged neck. The release of the adherent placenta required a partial omentectomy and left adnexectomy and was carefully removed following active bleeding from its detached margins. The newborn died of respiratory distress on the first day after birth. No autopsy was performed. Postoperative morbidity for the woman was minimal and she was discharged on the seventh post-operative day in good general condition. Abdominal pregnancies with a normal live foetus at such an advanced gestational age are extremely rare, and there are no available videos in the extant literature of the surgical procedure performed. Standardization of treatment principles, pre-operative preparation with imaging techniques (MRI, embolization of placental vessels) and adequately equipped and staffed neonatal units are necessary to optimize the foetus-maternal outcomes.
- 27 June 2023
- Vol. 27 (1) , 30-32
Open AccessAsymptomatic 39 Weeks Abdominal Pregnancy – Video Report of a Case Occurred in Ivory Coast Resulting in a Live Birth
Despite the current advances in antenatal care and imaging methodologies in obstetrics, cases of advanced abdominal pregnancies are still reported, mostly in low- and middle-income countries where frequently only a few perinatal checks are performed and where these methodologies are sometimes not adopted in obstetrical outpatient settings. We report the video of a case of a 20-year-old I gravida Ivorian patient, sent to CHU de T reichville in Abidjan, Ivory Coast, for management of abdominal 39 weeks pregnancy after routine antenatal care. She was asymptomatic with a live foetus in transverse lie position. The anamnesis revealed four prenatal checks without ultrasound evaluation, the first one at 24 weeks of pregnancy. Emergency median longitudinal sub-umbilical laparotomy incision was performed. Foetal extraction was realized by transplacental incision due to omental placental implantation. A live female baby weighting 3350 grams was delivered, presenting bilateral clubfeet and an enlarged neck. The release of the adherent placenta required a partial omentectomy and left adnexectomy and was carefully removed following active bleeding from its detached margins. The newborn died of respiratory distress on the first day after birth. No autopsy was performed. Postoperative morbidity for the woman was minimal and she was discharged on the seventh post-operative day in good general condition. Abdominal pregnancies with a normal live foetus at such an advanced gestational age are extremely rare, and there are no available videos in the extant literature of the surgical procedure performed. Standardization of treatment principles, pre-operative preparation with imaging techniques (MRI, embolization of placental vessels) and adequately equipped and staffed neonatal units are necessary to optimize the foetus-maternal outcomes.
- 27 June 2022
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 39 (8) , 1917-1926
Basal serum level of Δ4-androstenedione reflects the ovaries’ ability to respond to stimulation in IVF cycles: setting up a new reliable index of both ovarian reserve and response
Purpose Adequate androgen levels are necessary for regular follicular growth, progression beyond the pre-antral stage, and prevention of follicular atresia. The main purpose of this study was to investigate whether baseline androgen levels had a predictive value on stimulation outcomes in IVF cycles. The secondary purpose was to compare the possible predictive value of androgens with that of already known markers. Methods The study included 91 infertile patients aged 30–45 years awaiting the first IVF cycle. All women underwent the same stimulation protocol and the same starting dose of recombinant FSH. As stimulation outcomes, the number of follicles recruited, estradiol and progesterone levels on the day of trigger, the total dose of gonadotropins administered, and the number of oocytes collected were recorded. Multiple linear regression and multivariate logistic regression were used to evaluate the significant predictive value of the variables for response to controlled ovarian stimulation (COS). By studying the reliability of different markers, an attempt was made to develop a single index with the highest predictive value. Results Pearson’s correlation revealed a statistically significant inverse correlation between oocytes collected and age (r = − 0.333, p < 0.001) and a positive correlation with AMH (anti-müllerian hormone) (r = 0.360, p < 0.001), antral follicle count (AFC) (r = 0.639, p < 0.001), and androstenedione (Δ4-A) (r = 0.359, p < 0.001). No significant correlation was reported with FSH (r = − 0.133, p = 0.207) and total testosterone (r = 0.180, p = 0.088). In COS good responders, the G-index (= AMH ng/mL*AFC/Δ4-A ng/dL) revealed a significantly higher level (p < 0.001) than AMH, AFC, and Δ4-A alone. Conclusion Baseline serum Δ4-A, presumably crucial for ensuring a regular follicular growth, is a reliable marker of ovarian response to stimulation. Since the ovarian capacity to respond to gonadotropins does not depend exclusively on the presence of follicles, we suggest a new index, the G-index, able to contemplate both the ovarian reserve and the Δ4-A level.
- 27 June 2022
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 39 (8) , 1917-1926
Basal serum level of Δ4-androstenedione reflects the ovaries’ ability to respond to stimulation in IVF cycles: setting up a new reliable index of both ovarian reserve and response
Purpose Adequate androgen levels are necessary for regular follicular growth, progression beyond the pre-antral stage, and prevention of follicular atresia. The main purpose of this study was to investigate whether baseline androgen levels had a predictive value on stimulation outcomes in IVF cycles. The secondary purpose was to compare the possible predictive value of androgens with that of already known markers. Methods The study included 91 infertile patients aged 30–45 years awaiting the first IVF cycle. All women underwent the same stimulation protocol and the same starting dose of recombinant FSH. As stimulation outcomes, the number of follicles recruited, estradiol and progesterone levels on the day of trigger, the total dose of gonadotropins administered, and the number of oocytes collected were recorded. Multiple linear regression and multivariate logistic regression were used to evaluate the significant predictive value of the variables for response to controlled ovarian stimulation (COS). By studying the reliability of different markers, an attempt was made to develop a single index with the highest predictive value. Results Pearson’s correlation revealed a statistically significant inverse correlation between oocytes collected and age (r = − 0.333, p < 0.001) and a positive correlation with AMH (anti-müllerian hormone) (r = 0.360, p < 0.001), antral follicle count (AFC) (r = 0.639, p < 0.001), and androstenedione (Δ4-A) (r = 0.359, p < 0.001). No significant correlation was reported with FSH (r = − 0.133, p = 0.207) and total testosterone (r = 0.180, p = 0.088). In COS good responders, the G-index (= AMH ng/mL*AFC/Δ4-A ng/dL) revealed a significantly higher level (p < 0.001) than AMH, AFC, and Δ4-A alone. Conclusion Baseline serum Δ4-A, presumably crucial for ensuring a regular follicular growth, is a reliable marker of ovarian response to stimulation. Since the ovarian capacity to respond to gonadotropins does not depend exclusively on the presence of follicles, we suggest a new index, the G-index, able to contemplate both the ovarian reserve and the Δ4-A level.
- Open Access
Effects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics
Background: Glioblastoma is the most aggressive primary brain malignancy in adults, with a poor prognosis of about 14 months. Recent evidence ascribed to metformin (MET), an antihyperglycemic drug, the potential to reduce cancer incidence and progression, but the molecular mechanisms underlying these effects need to be better investigated. Methods: Here, we tested the efficacy of MET on n = 10 primary glioblastoma endothelial cells (GECs), by viability and proliferation tests, as MTT and Live/Dead assays, apoptosis tests, as annexin V assay and caspase 3/7 activity, functional tests as tube-like structure formation and migration assay and by mRNA and protein expression performed by quantitative real-time PCR analysis (qRT-PCR) and Western Blot, respectively. Results: Data resulting revealed a time- and μ-dependent ability of MET to decrease cell viability and proliferation, increasing pro-apoptotic mechanisms mediated by caspases 3/7. Also, MET impacted GEC functionality with a significant decrease of angiogenesis and invasiveness potential. Mechanistically, MET was able to interfere with sphingolipid metabolism, weakening the oncopromoter signaling promoted by sphingosine-1-phosphate (S1P) and shifting the balance toward the production of the pro-apoptotic ceramide. Conclusions: These observations ascribed to MET the potential to serve as add-on therapy against glioblastoma, suggesting a repurposing of an old, totally safe and tolerable drug for novel oncology therapeutics.
Open AccessEffects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics
Background: Glioblastoma is the most aggressive primary brain malignancy in adults, with a poor prognosis of about 14 months. Recent evidence ascribed to metformin (MET), an antihyperglycemic drug, the potential to reduce cancer incidence and progression, but the molecular mechanisms underlying these effects need to be better investigated. Methods: Here, we tested the efficacy of MET on n = 10 primary glioblastoma endothelial cells (GECs), by viability and proliferation tests, as MTT and Live/Dead assays, apoptosis tests, as annexin V assay and caspase 3/7 activity, functional tests as tube-like structure formation and migration assay and by mRNA and protein expression performed by quantitative real-time PCR analysis (qRT-PCR) and Western Blot, respectively. Results: Data resulting revealed a time- and μ-dependent ability of MET to decrease cell viability and proliferation, increasing pro-apoptotic mechanisms mediated by caspases 3/7. Also, MET impacted GEC functionality with a significant decrease of angiogenesis and invasiveness potential. Mechanistically, MET was able to interfere with sphingolipid metabolism, weakening the oncopromoter signaling promoted by sphingosine-1-phosphate (S1P) and shifting the balance toward the production of the pro-apoptotic ceramide. Conclusions: These observations ascribed to MET the potential to serve as add-on therapy against glioblastoma, suggesting a repurposing of an old, totally safe and tolerable drug for novel oncology therapeutics.
- Open Access
- 4 January 2022
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 20 (1) , 1-12
Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients
Background: Moving from the correlation between insulin-resistance and PCOS, metformin has been administered in some PCOS women improving ovulatory and metabolic functions and decreasing androgen levels. Inconsistency and unpredictability of response to metformin limit its extensive use. Aim of this study was to identify reliable predictors of response to metformin therapy for weight loss and reduction in plasma androgen levels using ANNs (artificial neural networks). Methods: One hundred eight consecutive women with PCOS (ESHRE/ASRM 2003 Rotterdam criteria) treated with metformin 1500 mg/day, at inclusion and every 6 months underwent to a complete clinical, endocrine/metabolic assessment and ultrasonographic evaluation. Therapy outcomes were BMI reduction (≥1 kg/m2) in overweight/obese and free-androgen-index (FAI) decrease (≥1%) in hyperandrogenemic women. Semantic connectivity maps (SCMs) were obtained through Auto-CM, a fourth generation ANN, to compare patients’ baseline clinical features to the treatment outcomes. Multivariate logistic regression analysis was used to assess the major predictor in drop-out patients and the associated risk. Results: At 6 months 54 out of 103 (52,4%) obese patients showed BMI reduction and 45 out of 89 (50,6%) hyperandrogenemic women showed FAI decrease. The further response rates at 12 months were 30,6 and 47%, respectively. SCMs showed a clear polarization for both the outcomes with elevated accuracy. Treatment responsiveness resulted strictly related to oligo-amenorrhea and hyperandrogenemia at baseline. In addition, lower serum testosterone levels at baseline were found to be the major predictor of treatment discontinuation. Conclusions: In women with PCOS, menstrual pattern imbalance and ovarian androgens excess are the best predictors of metformin response. They may pave the way for a rethinking of the criteria for evaluating hyperandrogenism in order to better define the large population included in the diagnosis of PCOS. Baseline plasma testosterone level can serve as a sensitive marker to predict treatment compliance.
- 4 January 2022
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 20 (1) , 1-12
Open AccessHyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients
Background: Moving from the correlation between insulin-resistance and PCOS, metformin has been administered in some PCOS women improving ovulatory and metabolic functions and decreasing androgen levels. Inconsistency and unpredictability of response to metformin limit its extensive use. Aim of this study was to identify reliable predictors of response to metformin therapy for weight loss and reduction in plasma androgen levels using ANNs (artificial neural networks). Methods: One hundred eight consecutive women with PCOS (ESHRE/ASRM 2003 Rotterdam criteria) treated with metformin 1500 mg/day, at inclusion and every 6 months underwent to a complete clinical, endocrine/metabolic assessment and ultrasonographic evaluation. Therapy outcomes were BMI reduction (≥1 kg/m2) in overweight/obese and free-androgen-index (FAI) decrease (≥1%) in hyperandrogenemic women. Semantic connectivity maps (SCMs) were obtained through Auto-CM, a fourth generation ANN, to compare patients’ baseline clinical features to the treatment outcomes. Multivariate logistic regression analysis was used to assess the major predictor in drop-out patients and the associated risk. Results: At 6 months 54 out of 103 (52,4%) obese patients showed BMI reduction and 45 out of 89 (50,6%) hyperandrogenemic women showed FAI decrease. The further response rates at 12 months were 30,6 and 47%, respectively. SCMs showed a clear polarization for both the outcomes with elevated accuracy. Treatment responsiveness resulted strictly related to oligo-amenorrhea and hyperandrogenemia at baseline. In addition, lower serum testosterone levels at baseline were found to be the major predictor of treatment discontinuation. Conclusions: In women with PCOS, menstrual pattern imbalance and ovarian androgens excess are the best predictors of metformin response. They may pave the way for a rethinking of the criteria for evaluating hyperandrogenism in order to better define the large population included in the diagnosis of PCOS. Baseline plasma testosterone level can serve as a sensitive marker to predict treatment compliance.
- 30 April 2021
- Published by Springer Nature in Reproductive Sciences
- Vol. 28 (12) , 3466-3472
“Add-Ons” for Assisted Reproductive Technology: Do Patients Get Honest Information from Fertility Clinics’ Websites?
“Add-on” procedures are actively promoted on some fertility clinic websites as proven means to improve IVF success rates, especially for couples with repeated implantation/IVF failures. However, the actual contribution of these interventions to live birth rates remains inconclusive. At present, little is known about the type and quality of the information provided on the IVF clinics’ websites regarding the merits of “add-ons.” A systematic evaluation of the quality of information on “add-on” procedures in fertility clinic websites was performed using 10-criteria structured questionnaire. We included English language websites that presented in the Google.com search engine after typing the following key-words:“endometrial scratching”(ES), “intralipid infusions”(ILI), “assisted hatching”(AHA), “PGT-A,” or “PGS”. In total, 254 websites were evaluated. In most cases, an accurate description of the “add-on” procedures was provided (78.8%). However, only a minority (12%) reported their undetermined effectiveness. The use of PGT-A was more often encouraged (52.8%) than ES (23.6%) and AHA (16%). The cost was infrequently presented (6.9%). Scientific references were only rarely provided for ILI, versus 12.7% for ES, 4.0% for AHA, and 5.6% for PGT-A. The information entry date was often missing. None of the websites reported the clinic’s pregnancy-rate following the “add-on” procedures. Information on “add-ons” available to patients from IVF clinic websites is often inaccurate. This could perpetuate false myths among infertile patients about these procedures and raises concern regarding possible commercial bias. It is imperative that IVF clinic websites will better communicate the associated risks and uncertainties of “add-ons” to prospective patients.
- 30 April 2021
- Published by Springer Nature in Reproductive Sciences
- Vol. 28 (12) , 3466-3472
“Add-Ons” for Assisted Reproductive Technology: Do Patients Get Honest Information from Fertility Clinics’ Websites?
“Add-on” procedures are actively promoted on some fertility clinic websites as proven means to improve IVF success rates, especially for couples with repeated implantation/IVF failures. However, the actual contribution of these interventions to live birth rates remains inconclusive. At present, little is known about the type and quality of the information provided on the IVF clinics’ websites regarding the merits of “add-ons.” A systematic evaluation of the quality of information on “add-on” procedures in fertility clinic websites was performed using 10-criteria structured questionnaire. We included English language websites that presented in the Google.com search engine after typing the following key-words:“endometrial scratching”(ES), “intralipid infusions”(ILI), “assisted hatching”(AHA), “PGT-A,” or “PGS”. In total, 254 websites were evaluated. In most cases, an accurate description of the “add-on” procedures was provided (78.8%). However, only a minority (12%) reported their undetermined effectiveness. The use of PGT-A was more often encouraged (52.8%) than ES (23.6%) and AHA (16%). The cost was infrequently presented (6.9%). Scientific references were only rarely provided for ILI, versus 12.7% for ES, 4.0% for AHA, and 5.6% for PGT-A. The information entry date was often missing. None of the websites reported the clinic’s pregnancy-rate following the “add-on” procedures. Information on “add-ons” available to patients from IVF clinic websites is often inaccurate. This could perpetuate false myths among infertile patients about these procedures and raises concern regarding possible commercial bias. It is imperative that IVF clinic websites will better communicate the associated risks and uncertainties of “add-ons” to prospective patients.
- 18 August 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 94 (1) , 85-89
Cord blood androgen levels of females from same sex and opposite sex twins – A pilot study
Objective Opposite sex twins have shown behavioral and reproductive differences between females and males. These differences may be determined by higher intrauterine levels of androgens among females that were exposed to a male co‐twin. The aim of this study was to compare cord blood androgen levels in females from same and opposite sex twins. Design A prospective study. In this pilot study we compared cord blood androgens (DHEA‐S, Δ‐4 Androstenedione, total testosterone ‐ TT) and sex hormone‐binding globulin (SHBG) levels in 20 females from same sex and 20 females from opposite sex dichorionic diamniotic twins. We used generalized estimating equation (GEE) modeling to assess differences in cord blood androgens between females from same‐sex twin pregnancies and females from opposite‐sex twin pregnancies. Patients Twenty opposite‐sex twin pairs (female‐male twins) and 20 same‐sex twin pairs (female‐female). Measurements Cord blood total Testosterone, Δ‐4 Androstenedione, DHEA‐S and Sex hormone‐binding globulin (SHBG) levels Results No difference in the levels of androgens as Δ‐4 Androstenedione, total testosterone and SHBG were identified between females that were exposed to a female co‐twin compared with females that were exposed to a male co‐twin. DHEA‐S levels were significantly lower among females from opposite‐sex twins compared with females from same sex twins. Conclusions Our preliminary data do not support the hypothesis that females exposed to male co‐twins are exposed to higher levels of androgens in utero compared with females exposed to female co‐twins. Further studies are needed to explain the reported behavioral and reproductive differences among opposite‐sex twins.
- 18 August 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 94 (1) , 85-89
Cord blood androgen levels of females from same sex and opposite sex twins – A pilot study
Objective Opposite sex twins have shown behavioral and reproductive differences between females and males. These differences may be determined by higher intrauterine levels of androgens among females that were exposed to a male co‐twin. The aim of this study was to compare cord blood androgen levels in females from same and opposite sex twins. Design A prospective study. In this pilot study we compared cord blood androgens (DHEA‐S, Δ‐4 Androstenedione, total testosterone ‐ TT) and sex hormone‐binding globulin (SHBG) levels in 20 females from same sex and 20 females from opposite sex dichorionic diamniotic twins. We used generalized estimating equation (GEE) modeling to assess differences in cord blood androgens between females from same‐sex twin pregnancies and females from opposite‐sex twin pregnancies. Patients Twenty opposite‐sex twin pairs (female‐male twins) and 20 same‐sex twin pairs (female‐female). Measurements Cord blood total Testosterone, Δ‐4 Androstenedione, DHEA‐S and Sex hormone‐binding globulin (SHBG) levels Results No difference in the levels of androgens as Δ‐4 Androstenedione, total testosterone and SHBG were identified between females that were exposed to a female co‐twin compared with females that were exposed to a male co‐twin. DHEA‐S levels were significantly lower among females from opposite‐sex twins compared with females from same sex twins. Conclusions Our preliminary data do not support the hypothesis that females exposed to male co‐twins are exposed to higher levels of androgens in utero compared with females exposed to female co‐twins. Further studies are needed to explain the reported behavioral and reproductive differences among opposite‐sex twins.